An application was submitted to the European Medicines Agency seeking approval for treatment with sugemalimab in stage 3 ...

Hollings Cancer Center, US, has enrolled the first subject in the Phase II/III FORTIFI-NH01 trial of ficerafusp alfa to treat ...

CEL-SCI reports new data. Treatment with Multikine resulted in up to 95% improvement in Quality of Life for Head and Neck ...

EVM14 received U.S. FDA clearance for its IND application, becoming Everest's first internally discovered program, and the first mRNA therapeutic cancer vaccine to be cleared for global clinical ...

HealthDay News — In a clinical practice guideline issued by the American Society for Radiation Oncology and published online Feb. 27 in Practical Radiation Oncology, evidence-based recommendations are ...

HC Wainwright reissued their buy rating on shares of InflaRx (NASDAQ:IFRX – Free Report) in a report issued on Friday morning ...

Stevens was hit in the spine and underwent three months of rehabilitation at the Illinois Rehabilitation Institute of Chicago ...

It’s a myth that you can’t get burnt on cloudy days or that window glass stops the transmission of harmful rays. There is ...

The European Commission (EC) and the Medicines and Healthcare products Regulatory Agency (MHRA) have approved sugemalimab in combination with platinum-based chemotherapy for the first-line treatment ...

Henlius (2696.HK) announced its 2024 annual results. During the reporting period, Henlius' total revenue reached approximately ...

The government of Alberta has announced a collaboration with Siemens Healthineers and the Alberta Cancer Foundation, ...

Among other functions, the NK cells (natural killers, a type of lymphocyte forming part of the immune system) have the capacity to detect and eliminate cancer cells. But in some cases they cannot ...